Repligen Corporation will announce Q3 2025 financial results on October 28, followed by a conference call at 8:30 a.m. ET.
Quiver AI Summary
Repligen Corporation announced that it will release its third quarter 2025 financial results on October 28, 2025. The financial results will be discussed during a conference call at 8:30 a.m. ET, which can be accessed via a toll-free number for domestic callers and an international line. A webcast of the call will also be available on the company's website, with both the call and webcast archived for later access. Repligen is a global life sciences company that specializes in innovative bioprocessing technologies for manufacturing biological drugs, with operations based in Waltham, Massachusetts and several key sites worldwide. The press release includes forward-looking statements that may involve risks and uncertainties, and the company disclaims any obligation to update these statements.
Potential Positives
- Repligen Corporation will report its third quarter 2025 financial results on October 28, 2025, indicating transparency and commitment to keeping investors informed.
- The company will host a conference call to discuss business updates and financial results, providing opportunities for direct engagement with stakeholders.
- Repligen is recognized for developing innovative bioprocessing technologies, highlighting its position as a leader in the life sciences sector.
Potential Negatives
- Announcement of third quarter financial results may indicate underlying issues if performance is expected to be poor or inconsistent.
- The emphasis on forward-looking statements may raise concerns among investors about the company's future outlook and potential volatility.
- The lack of detailed financial performance information in the release may lead to speculation and anxiety among investors regarding the company's actual financial health.
FAQ
When will Repligen Corporation announce its Q3 2025 financial results?
Repligen Corporation will report its third quarter 2025 financial results on Tuesday, October 28, 2025.
How can I access the Repligen conference call?
The conference call can be accessed by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers.
Will there be a webcast of the conference call?
Yes, a webcast will be available through the Investor Relations section of the Company’s website.
What time is the Repligen conference call scheduled?
The conference call is scheduled for 8:30 a.m. ET on October 28, 2025.
Where can I find more information about Repligen Corporation?
Additional information about Repligen Corporation can be found on their website at www.repligen.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RGEN Congressional Stock Trading
Members of Congress have traded $RGEN stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 2 purchases worth up to $30,000 on 07/22, 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RGEN Insider Trading Activity
$RGEN insiders have traded $RGEN stock on the open market 12 times in the past 6 months. Of those trades, 1 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
- ANTHONY HUNT has made 0 purchases and 11 sales selling 55,558 shares for an estimated $6,780,076.
- MARTIN D MADAUS purchased 1,800 shares for an estimated $201,830
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RGEN Hedge Fund Activity
We have seen 205 institutional investors add shares of $RGEN stock to their portfolio, and 241 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 962,139 shares (-12.7%) from their portfolio in Q2 2025, for an estimated $119,670,848
- FMR LLC added 880,900 shares (+120.3%) to their portfolio in Q2 2025, for an estimated $109,566,342
- MACQUARIE GROUP LTD removed 819,753 shares (-90.1%) from their portfolio in Q2 2025, for an estimated $101,960,878
- POINT72 ASSET MANAGEMENT, L.P. added 796,745 shares (+71.4%) to their portfolio in Q2 2025, for an estimated $99,099,143
- BLACKROCK, INC. removed 737,257 shares (-10.8%) from their portfolio in Q2 2025, for an estimated $91,700,025
- MILLENNIUM MANAGEMENT LLC added 681,342 shares (+3424.3%) to their portfolio in Q2 2025, for an estimated $84,745,317
- COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS added 400,970 shares (+3219.3%) to their portfolio in Q2 2025, for an estimated $49,872,648
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RGEN Analyst Ratings
Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- HSBC issued a "Buy" rating on 10/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
- Wells Fargo issued a "Overweight" rating on 07/30/2025
- RBC Capital issued a "Outperform" rating on 07/30/2025
- Stephens & Co. issued a "Overweight" rating on 07/22/2025
To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.
$RGEN Price Targets
Multiple analysts have issued price targets for $RGEN recently. We have seen 9 analysts offer price targets for $RGEN in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Daniel Markowitz from Evercore ISI Group set a target price of $175.0 on 10/07/2025
- Luke Sergott from Barclays set a target price of $160.0 on 10/02/2025
- Yessica Sanchez from HSBC set a target price of $150.0 on 10/01/2025
- Matthew Stanton from Jefferies set a target price of $135.0 on 09/12/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $180.0 on 09/03/2025
- Brandon Couillard from Wells Fargo set a target price of $175.0 on 07/30/2025
- Conor McNamara from RBC Capital set a target price of $204.0 on 07/30/2025
Full Release
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025.
The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are
“inspiring advances in bioprocessing”
for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at
www.repligen.com
, and follow us on
LinkedIn
.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
[email protected]
